Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.

After learning doctors weren’t prescrbing its migraine drug Nurtec because they assumed insurance coverage would be a hassle, the company ...

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

Pfizer proudly flaunts its “World’s Most Ethical Companies” award, but this honor is a pay-to-play scheme, not a genuine ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

Pfizer has beaten Wall Street's revenue estimate ... [$2.31 to $3.08] due to my more optimistic sales expectations for Nurtec ODT/Vydura, Padcev, Adcetris, and Cibinqo, as well as the launch ...

Pfizer reported fourth-quarter 2024 adjusted ... Newly acquired product Nurtec ODT/Vydura contributed $392 million in the quarter, which rose 39% year over year, driven by strong demand in the ...